Benign Gynecological Diseases and SERMs
作者： Stefano Palomba , Fulvio Zullo
关键词: Uterine leiomyoma 、 Adjuvant 、 Raloxifene 、 Endometrial hyperplasia 、 Pelvic pain 、 Medicine 、 Oncology 、 Internal medicine 、 Tamoxifen 、 Breast cancer 、 Uterus
摘要: At present, the only SERMs routinely used in clinical practice are tamoxifen and raloxifene. Tamoxifen is essentially as adjuvant treatment women with breast cancer. Its use related to estrogenic effects on uterus. Specifically, can be associated an increase not endometrial hyperplasia cancer risk but also uterine leiomyoma dimensions a of developing active endometriotic lesions.
springer.com
elsevier.com
springerlink.com参考文章(105)
Lorenzo Abad de Velasco, Antonio Cano, Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen European Journal of Obstetrics & Gynecology and Reproductive Biology. ,vol. 109, pp. 234- 235 ,(2003) , 10.1016/S0301-2115(03)00004-6
KRISTOF CHWALISZ, RAMESH GARG, ROBERT M. BRENNER, GERD SCHUBERT, WALTER ELGER, Selective Progesterone Receptor Modulators (SPRMs) Annals of the New York Academy of Sciences. ,vol. 955, pp. 373- 388 ,(2002) , 10.1111/J.1749-6632.2002.TB02798.X
Stefan Jirecek, Andreas Lee, Imre Pavo, Gerald Crans, Wolfgang Eppel, Rene Wenzl, Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertility and Sterility. ,vol. 81, pp. 132- 136 ,(2004) , 10.1016/J.FERTNSTERT.2003.06.009
Oscar Sadan, Shimon Ginath, Dror Sofer, Sigi Rotmensch, Abraham Debby, Marek Glezerman, Haim Zakut, The role of tamoxifen in the treatment of symptomatic uterine leiomyomata — a pilot study European Journal of Obstetrics & Gynecology and Reproductive Biology. ,vol. 96, pp. 183- 186 ,(2001) , 10.1016/S0301-2115(00)00468-1
John F.R. Robertson, Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treatment Reviews. ,vol. 30, pp. 695- 706 ,(2004) , 10.1016/J.CTRV.2004.04.003
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators., None, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA. ,vol. 282, pp. 637- 645 ,(1999) , 10.1001/JAMA.282.7.637
Emre Seli, Murat Berkkanoglu, Aydin Arici, Pathogenesis of endometriosis Obstetrics and Gynecology Clinics of North America. ,vol. 24, pp. 219- 233 ,(1997) , 10.1016/S0889-8545(02)00052-9
Gruppo Italiano per lo Studio dell'Endometriosi, None, Ablation of lesions or no treatment in minimal–mild endometriosis in infertile women: a randomized trial Human Reproduction. ,vol. 14, pp. 1332- 1334 ,(1999) , 10.1093/HUMREP/14.5.1332
Stefano Palomba, Fulvio Zullo, Francesco Orio, Gaetano Lombardi, Does raloxifene inhibit the growth of uterine fibroids Fertility and Sterility. ,vol. 81, pp. 1719- 1720 ,(2004) , 10.1016/J.FERTNSTERT.2004.03.009
Stefano Palomba, Francesco Orio, Michele Morelli, Tiziana Russo, Massimilano Pellicano, Carmine Nappi, Pasquale Mastrantonio, Gaetano Lombardi, Annamaria Colao, Fulvio Zullo, Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. The Journal of Clinical Endocrinology and Metabolism. ,vol. 87, pp. 4476- 4481 ,(2002) , 10.1210/JC.2002-020780